Exploring the Multi-targeting Phytoestrogen Potential of Calycosin for Cancer Treatment: A Review

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2024 May 3

PMID 38701310

Authors

Fangbing Ren

Yanhui Ma

Kexin Zhang

Youhong Luo

Ruiyan Pan

Jingwen Zhang

Chengxia Kan

Ningning Hou

Fang Han

Xiaodong Sun

Affiliations

Soon will be listed here.

Abstract

Cancer remains a significant challenge in the field of oncology, with the search for novel and effective treatments ongoing. Calycosin (CA), a phytoestrogen derived from traditional Chinese medicine, has garnered attention as a promising candidate. With its high targeting and low toxicity profile, CA has demonstrated medicinal potential across various diseases, including cancers, inflammation, and cardiovascular disease. Studies have revealed that CA possesses inhibitory effects against a diverse array of cancers. The underlying mechanism of action involves a reduction in tumor cell proliferation, induction of tumor cell apoptosis, and suppression of tumor cell migration and invasion. Furthermore, CA has been shown to enhance the efficacy of certain chemotherapeutic drugs, making it a potential component in treating malignant tumors. Given its high efficacy, low toxicity, and multi-targeting characteristics, CA holds considerable promise as a therapeutic agent for cancer treatment. The objective of this review is to present a synthesis of the current understanding of the antitumor mechanism of CA and its research progress.

Citing Articles

The Astragalus Membranaceus Herb Attenuates Leukemia by Inhibiting the FLI1 Oncogene and Enhancing Anti-Tumor Immunity.

Yu K, Tang Y, Wang C, Liu W, Hu M, Hu A Int J Mol Sci. 2025; 25(24.

PMID: 39769192 PMC: 11676164. DOI: 10.3390/ijms252413426.

Yu-Ping-Feng-San improve the immunosuppression of microenvironment in hepatocellular carcinoma by promoting the maturation of DCs through the JAK2-STAT3 pathway.

Yao F, Yuan Q, Yan Y, Liang G, Zhou L, Xu H Sci Rep. 2024; 14(1):31522.

PMID: 39733089 PMC: 11682348. DOI: 10.1038/s41598-024-83197-7.

Species of the Sections and of the Genus (Fabaceae): Taxonomy, Distribution, Chromosomes, Genomes, and Phylogeny.

Yurkevich O, Samatadze T, Zoshchuk S, Amosova A, Muravenko O Int J Mol Sci. 2024; 25(15).

PMID: 39126057 PMC: 11312482. DOI: 10.3390/ijms25158489.

References

Nie X, Zhou Y, Li X, Xu J, Pan X, Yin R . Calycosin down-regulates c-Met to suppress development of glioblastomas. J Biosci. 2019; 44(4). View

El-Kott A, Al-Kahtani M, Shati A . Calycosin induces apoptosis in adenocarcinoma HT29 cells by inducing cytotoxic autophagy mediated by SIRT1/AMPK-induced inhibition of Akt/mTOR. Clin Exp Pharmacol Physiol. 2019; 46(10):944-954. DOI: 10.1111/1440-1681.13133. View

Tang L, Feng Q, Zhao J, Dong L, Liu W, Yang C . Involvement of UDP-glucuronosyltranferases and sulfotransferases in the liver and intestinal first-pass metabolism of seven flavones in C57 mice and humans in vitro. Food Chem Toxicol. 2012; 50(5):1460-7. DOI: 10.1016/j.fct.2012.01.018. View

Thoompumkal I, Rehna K, Anbarasu K, Mahalingam S . Leucine Zipper Down-regulated in Cancer-1 (LDOC1) interacts with Guanine nucleotide binding protein-like 3-like (GNL3L) to modulate Nuclear Factor-kappa B (NF-κB) signaling during cell proliferation. Cell Cycle. 2016; 15(23):3251-3267. PMC: 5176145. DOI: 10.1080/15384101.2016.1242534. View

Baniak N, Senger J, Ahmed S, Kanthan S, Kanthan R . Gastric biomarkers: a global review. World J Surg Oncol. 2016; 14(1):212. PMC: 4982433. DOI: 10.1186/s12957-016-0969-3. View

Meng L, Hsu J, Tsai R . GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest. Oncogene. 2010; 30(14):1716-26. PMC: 3072457. DOI: 10.1038/onc.2010.550. View

Wu G, Niu M, Qin J, Wang Y, Tian J . Inactivation of Rab27B-dependent signaling pathway by calycosin inhibits migration and invasion of ER-negative breast cancer cells. Gene. 2019; 709:48-55. DOI: 10.1016/j.gene.2019.04.005. View

Simpson E, Brown H . Understanding osteosarcomas. JAAPA. 2018; 31(8):15-19. DOI: 10.1097/01.JAA.0000541477.24116.8d. View

Levin V, Jiang X, Kagan R . Estrogen therapy for osteoporosis in the modern era. Osteoporos Int. 2018; 29(5):1049-1055. DOI: 10.1007/s00198-018-4414-z. View

10.

Chaouhan H, Li X, Sun K, Wang I, Yu T, Yu S . Calycosin Alleviates Paraquat-Induced Neurodegeneration by Improving Mitochondrial Functions and Regulating Autophagy in a Model of Parkinson's Disease. Antioxidants (Basel). 2022; 11(2). PMC: 8868496. DOI: 10.3390/antiox11020222. View

11.

Li S, Wang Y, Feng C, Wu G, Ye Y, Tian J . Calycosin Inhibits the Migration and Invasion of Human Breast Cancer Cells by Down-Regulation of Foxp3 Expression. Cell Physiol Biochem. 2017; 44(5):1775-1784. DOI: 10.1159/000485784. View

12.

Akhurst R, Derynck R . TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol. 2001; 11(11):S44-51. DOI: 10.1016/s0962-8924(01)02130-4. View

13.

Qu N, Qu J, Huang N, Zhang K, Ye T, Shi J . Calycosin induces autophagy and apoptosis Sestrin2/AMPK/mTOR in human papillary thyroid cancer cells. Front Pharmacol. 2023; 13:1056687. PMC: 9800829. DOI: 10.3389/fphar.2022.1056687. View

14.

Zhou Y, Liu Q, Liu C, Lin L . Calycosin induces apoptosis in human ovarian cancer SKOV3 cells by activating caspases and Bcl-2 family proteins. Tumour Biol. 2015; 36(7):5333-9. DOI: 10.1007/s13277-015-3194-8. View

15.

Zhang Y, Wei F, Zhang J, Hao L, Jiang J, Dang L . Bisphenol A and estrogen induce proliferation of human thyroid tumor cells via an estrogen-receptor-dependent pathway. Arch Biochem Biophys. 2017; 633:29-39. DOI: 10.1016/j.abb.2017.09.002. View

16.

Kong L, Li X, Wang H, He G, Tang A . Calycosin inhibits nasopharyngeal carcinoma cells by influencing EWSAT1 expression to regulate the TRAF6-related pathways. Biomed Pharmacother. 2018; 106:342-348. DOI: 10.1016/j.biopha.2018.06.143. View

17.

Tian J, Wang Y, Zhang X, Ren Q, Li R, Huang Y . Calycosin inhibits the in vitro and in vivo growth of breast cancer cells through WDR7-7-GPR30 Signaling. J Exp Clin Cancer Res. 2017; 36(1):153. PMC: 5667511. DOI: 10.1186/s13046-017-0625-y. View

18.

Malumbres M, Barbacid M . Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009; 9(3):153-66. DOI: 10.1038/nrc2602. View

19.

Wu C, Li M, Meng H, Liu Y, Niu W, Zhou Y . Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019; 62(5):640-647. DOI: 10.1007/s11427-018-9461-5. View

20.

Ruan J, Li S, Li Y, Wu W, Lee S, Yan R . The Presystemic Interplay between Gut Microbiota and Orally Administered Calycosin-7-O-β-D-Glucoside. Drug Metab Dispos. 2015; 43(10):1601-11. DOI: 10.1124/dmd.115.065094. View